Clene Inc (CLNN) FinancialsCLNNClene Inc

Clene Inc (CLNN) generates its revenue primarily from Supplements, which accounts for 100.0% of total sales, equivalent to $108.00K. Understanding this concentration is critical for investors evaluating how CLNN navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Clene Inc maintains a gross margin of 60.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -5941.11%, while the net margin is -14915.56%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively CLNN converts its operational activities into shareholder value.

In the context of the broader market, CLNN competes directly with industry leaders such as SCYX and ATYR. With a market capitalization of $59.75M, it holds a leading position in the sector. When comparing efficiency, CLNN's gross margin of 60.00% stands against SCYX's 100.00% and ATYR's N/A. Such benchmarking helps identify whether Clene Inc is trading at a premium or discount relative to its financial performance.

Clene's total revenue for Q2 2026 was $90,000, with a net income loss of -$13,424,000, indicating ongoing financial struggles. However, the gross margin remains high at 60%, showing potential for profitability if revenues increase.